PerkinElmer agrees to acquire SIRION Biotech

news-releasesSIRION Biotech GmbH
July 30th 2021

Martinsried, Germany: – Europe’s leading supplier of viral vector technologies, SIRION Biotech, has entered into an agreement to be acquired by US-based life sciences solutions provider PerkinElmer, Inc.

The planned acquisition by PerkinElmer, expected to be finalized during the third quarter of 2021, brings SIRION’s viral vector engineering and manufacture solutions to complement PerkinElmer’s growing position in cell and gene therapy research and development. This will allow SIRION to accelerate its leadership in viral vector technologies, with increased access to genomics analysis, gene editing and base editing technologies, as well as boosted  global infrastructure and reach.

Boosting Horizon Discovery portfolio

The addition of SIRION’s offerings will complement PerkinElmer’s Horizon Discovery portfolio which includes gene editing and modulation tools for CRISPR, CRISPRi and RNAi, custom cell lines for bio production and base editing technologies.

The projected acquisition will further broaden PerkinElmer’s existing cell and gene research solutions featuring industry-leading high content, in vivo, and cell painting screening technologies; innovative immunoassays; cell plate readers; and advanced automation, microfluidics and informatics and analytical platforms.

Growing SIRION’s viral vector leadership

Headquartered in Munich, Germany, privately held SIRION has approximately 50 employees based in Germany, the U.S. and France. The company has established a strong licensing portfolio leveraged by over a dozen major pharmaceutical and biotech players researching more than 25 diseases and conditions.

Commenting on the acquisition agreement, Dr. Christian Thirion, founder and CEO of SIRION, said it would be positive both for the company and its customers.

“Our team is excited to work with PerkinElmer to continue to grow our leading position in viral vector technologies for cell and gene therapy. We will benefit greatly from becoming part of the PerkinElmer portfolio, with increased access to genomics analysis, gene editing and base editing technologies, as well as a strong global infrastructure and reach,” said Dr. Thirion.

Innovative SIRION payload transport

Dr. Prahlad Singh, president and chief executive officer of PerkinElmer, commented: “Seventy percent of gene therapy trials today leverage viral vector approaches and we expect this to remain strong going forward given the demand for targeted, high-payload delivery in treating diseases like cancer.”

“By combining SIRION’s innovative payload transport technology with our existing Horizon genetic material editing tools and phenotypic research solutions, we will be able to support organizations’ cell and gene therapy workflows as they look to streamline and accelerate their efforts,” Dr. Singh added.

About PerkinElmer

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. It strategically partners with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Its dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. In 2020, the company reported revenues of approximately $3.8 billion, serving customers in 190 countries.

Further information PerkinElmer’s full range of life sciences solutions, Informatics and OneSource services at:

About SIRION Biotech

SIRION Biotech began its customer business in 2007 in Munich, setting their goal to spark a new generation of viral vector technologies for gene and cell therapy as well as vaccination development. This meant building novel, all-encompassing viral vector platforms for lenti-, adeno-, and adeno-associated viruses which expedite its partners’ advances in the drug, cosmetics, and food industries.  To date SIRION has completed over 2000 projects of all sizes, working closely with over 200 independent customer groups from academia and industry.


Click on SIRION Biotech Viral Vectors to learn more about custom adenovirus, lentivirus and adeno-associated viral vector services.
Click on PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech to view source release on

Succeed with Sirion

LentiBOOST® - Lentiviral Transduction Enhancer For Clinical Applications

PerkinElmer agrees to acquire SIRION Biotech

Dr. Christian Thirion, CEO CTO and Founder, SIRION Biotech GmbH